R&D | October 29, 2025
Advancing toward Phase 2a evaluation in chemotherapy-related pain, a condition with no approved treatments and potential for FDA Fast Track designation
Arora brings over 30 years of experience in the pharmaceutical and healthcare industry
Mesalamine suppositories are indicated for the treatment of mildly to moderately active ulcerative proctitis
In the next five years, an additional 75,000 seats are expected to be added across both undergraduate and postgraduate levels
With milestone-linked funding of Rs. 5–25 crore per project (and up to Rs. 50 crore in exceptional cases), the Mission will support projects that bring impactful MedTech solutions to market
The event will be attended by 35,000+ industry professionals
The acquisition will follow the planned separation of Avidity’s early-stage precision cardiology programs into a new, independent company
Agreement adds a new preclinical ADC with potential for enhanced anti-tumour activity and best-in-class profile
The company's net income attributable to equity holders dropped to €2.80 billion from €2.82 billion last year
Subscribe To Our Newsletter & Stay Updated
